Try our Advanced Search for more refined results
Life Sciences - January, 2019
343 articles
- 8 Highlights As Trump Targets Drug-Rebate Kickback Shield
- Panel Leans Toward Valsartan MDL, But Grapples With Scope
- Abilify MDL Plaintiffs Ordered To Defend Their Cases
- How Patent Litigation Changed In 2018
- Delaware Outstrips Texas As Top Patent Hotspot Of 2018
- Patent Injunctions Drop Sharply In 2018
- Despite Drop In AIA Reviews, PTAB Hasn't Lost Its Luster
- J&J Toxicologist Defends Co.'s Talc As 'Clean' At Cancer Trial
- AbbVie, Janssen's $3B Imbruvica Faces First Generic Threat
- Cannabis Cos.' Use Of Foreign Tax Credits May Draw IRS FireÂ
- 1st Circ. Revives Fraud Claims In Lexapro, Celexa MDL
- Feds Urge Guilty Verdict For Ex-Pharma CEO In $100M Fraud
- Shareholder Says AbbVie Hid Kickback, Buyback Schemes
- Deals Rumor Mill: Brookfield, Elliott, ConocoPhillips
- DOJ Ends Saline Price-Fixing Probe Against Baxter
- Blood Pressure Med Recalls Cost Us Double, Payers Say
- What Lawyers Can Do To Prevent And Combat Burnout
- The On-Sale Bar After High Court Helsinn Ruling
- J&J's Ethicon Slammed With $41M Verdict In Philly Mesh Case
- Purdue Loses Bid To Keep Mass. Allegations Under Wraps
- Disbarred Atty's Firm Gets $7M In Dow Nuclear Waste Case
- Synergy Execs Get Incentive Pay If Ch. 11 Sale Reaches $214M
- Pharma Fraudsters To Pay Valeant $11.8M Over Kickback Plot
- Pathology Lab Strikes $64M Deal Over DOJ Kickback Claims
- Judge Muffed Ex-Shkreli Atty's Disclosure Duty, Experts Say
- China Proposes Rules For New Tech-Focused Trading Venue
- J&J Pelvic Mesh Patient Endured 'Hell,' Pa. Jury Told
- Key Attys In Boston Scientific Pelvic Mesh MDL To Get $366M
- J&J Pushes Pa. Justices To Limit Risperdal Claims Window
- House Dems Want Insulin Pricing Info From Lilly, Novo, Sanofi
- Boston's Opioid Suit Won't Get Pulled Into Federal Court
- Convicted Doc Tells 2nd Circ. Drug Trial Trades Were Legal
- Antares Faces Records Suit Over Testosterone Drug Troubles
- Invisalign Maker Wasn't Straight About Discounts: Investor
- DOJ Defends Bayer-Monsanto Deal As 'Victory' For Farmers
- The Latest Developments In Antitrust Class Certification
- Dewpoint Therapeutics Lands $60M In Series A Funding
- Approaching Antibody Patents After Amgen V. Sanofi
- 7th Circ. Orders New Trial In Bull Semen-Sorting IP Row
- 9th Circ. Allows Row Over ACA Birth Control Rules To Proceed
- Ex-CEO Tells Chancery Salix Must Pay Her Legal Costs
- USPTO Issues Patent For Cannabis Toothpaste, Mouthwash
- Chinese Engineer Gets 27 Mos. For Trade Secret Theft In US
- HHS Report Card: Attys Grade Health Secretary's 1st Year
- SEC Settles With 4 Cos. Over Alleged Internal Control Failures
- Fresenius Extends $2B Merger Deadline After Shutdown
- Bellwether Trial In Opioid MDL Delayed Another 7 Weeks
- Celgene Says Drug Buyers' Second Try For Cert. No Better
- Opko Shareholder Says CEO's Scandal Sent Stocks To 'Abyss'
- J&J Pushed Risperdal Despite Breast-Growth Risk, Jury Hears
- Fed. Circ. Upholds Rejection Of Blood Sugar Monitor Patent
- Energy Co. Seeks To Speed Up IPO Now That Shutdown Over
- High Court Outlook For False Claims Act Cases In 2019
- Grassley Vows Scrutiny Of Rising Insulin Prices
- Former Alston & Bird Attorney Named Humana GC
- Insuring The Ever-Growing Cannabis Industry: Part 1
- BakerHostetler Atty Accused Of Misusing Info In Opioid MDL
- Chinese Biotech Co. Says Gov't Bias Behind H-1B Visa Denials
- Investor Sues Drugmaker Over Lack Of Control Group In Trials
- Fed. Circ. Medical Device IP Case Highlights ITC Tools
- An Unclear Path For Microbiome-Based Products At FDA
- Cancer Victim's Atty Takes Heat From Judge In Monsanto MDL
- Bitter Backlash Greets Wider Medicare Drug Negotiations
- Punitives Promise Fiercer Fight In Philly Risperdal Trial
- Pharmacy Loses $20M In Its Suit Against Express Scripts
- IPOs Still Face Uncertainty Even As Government Reopens
- J&J May Get Lifeline In Talc Trials From Mo. High Court
- Feds Want FCA Suit Over $21M Kickback Scheme To Proceed
- 'Embarrassing' Purdue Info To Come Out In Mass. Opioid Suit
- Chiesa Shahinian Adds Ex-Pharma Counsel, Prosecutor In NJ
- Mallinckrodt, Express Scripts Must Face Antitrust Suit In Ill.
- German Co. Loses 3 Patents As Suit Against J&J Backfires
- Ex-Insys Execs Driven By Greed To Bribe Doctors, Jury Hears
- Can 'Bundle' Payment Plans Shield Against FCA Liability?
- 15 Minutes With Bristol-Myers Squibb's General Counsel
- 2018 FDA Enforcement Review: Drugs, Biologics And Devices
- Ex-CEO Asks 2nd Circ. For Bail During Valeant Fraud Appeal
- Fed. Circ. Ruling Clears Path For Longer Drug Patent Terms
- The Startup Drugmaker's Post-Helsinn Survival Guide
- More Mass. Claims Against Purdue To Come Out, Judge Says
- Abbott Labs, St. Jude Avoid Suit Over Battery Defects Again
- Device Maker Ev3 Cops To Improper Sales, Pays $18M
- J&J Knew Hip Implants A 'Disaster,' Jury Hears In Retrial
- Indivior Wins Temporary Block On Alvogen Suboxone Generic
- Investors Fight Perrigo's Attempt To Escape Mylan Suit
- Cannabis Cos. Adopting Biotech's Patent Playbook
- Supreme Court Leans Toward Reversal In Merck V. Albrecht
- J&J Didn't Warn Of Talc's Baby Asphyxiation Risks, Jury Told
- Sen. Bill Would Let HHS Prevent Another 'EpiPen Fiasco'
- Split Fed. Circ. OKs $23.5M Medtronic Loss Over Spine IP
- Sanofi Suit Against Mylan To Stay In EpiPen MDL, For Now
- Insys Trial A Salvo In 'Militaristic' Gov't Attack On Opioids
- No Redo On Asacol Class Decertification At 1st Circ.
- Law Schools Should Be More Like Medical Centers
- Deals Rumor Mill: Saudi Aramco, Zambon, Anbang
- Greenberg Traurig Nabs Former 23andMe Privacy Officer
- 7th Circ. Takes Narrow View Of ADEA For Outside Applicants
- FCA Co. Torches DOJ Effort To Scuttle Suits
- Dexcom Defective Device Suit Sent Back To State Court
- Merck Can't Arbitrate Antitrust Suit Over Vaccine Bundles
- Gossamer Bio Seeks $230M IPO Amid Government Shutdown
- Boston Scientific's Del. Merger Trial Still A Go For April
- Fed. Circ. Slams 'Unfair' USPTO Patent Term Adjustment Regs
- Dry Mouth Line Can Stay On Market, Without GSK TMs In Ads
- Deals Rumor Mill: J&J, Union Life, Edcon
- 5 NY Doctors Denounce DOJ Charges Of Insys Kickbacks
- Endo Slams DQ Bid For BakerHostetler Atty In Opioid MDL
- J&J Baby Powder Cover-Up Cost Workers Millions, Suit Says
- Sheppard Mullin Nabs FDA Pro From Sidley Austin
- Pharma Co. Can't Sue FDA Over Rival's Opioid Approval
- Archer Daniels Escapes Bulk Of Deadly Horse Feed Suit
- Scientist Calls Studies Touted By J&J 'Dubious' At Talc Trial
- Walgreens Pays $269M In Milestone FCA Deals
- Valeant Copycat Drug Row Can Stay In Calif., Judge Rules
- Valeant Urges Fed. Circ. To Revive Antifungal Patent
- Direct Buyers Fight GSK, Teva's Bid To Stay Lamictal Suit
- 'On Sale' Ruling Shows Need For Earlier Patent Applications
- Hologic Settles Fujifilm's IP, Antitrust Mammography Suit
- J&J To Pay States $120M For False Hip Implant Promos
- Deals Rumor Mill: Fawaz Alhokair, Saudi Aramco, Colfax
- Consumer Orgs Say NAFTA 2.0 Will Keep Drug Prices High
- Courts Are Getting It Right On Litigation Funding Discovery
- 8 Promo Pitfalls Pharma Compliance Chiefs Need To Know
- FDA Releases Guidance On Clearing New Medical Devices
- Fed. Circ. Urged Not To Review Venue In $20M Cialis IP Row
- International Law In 2018: Key Developments
- High Court Says AIA Did Not Change Meaning Of On-Sale Bar
- EU Eyeing Opening Markets For Biosimilar, Generic Drugs
- Drug Distributors Can't Appeal RICO Ruling In Opioid MDL
- UnitedHealth Sues Generic-Drug Makers For Price-Fixing
- Pharma Investor Says $180M Deal Proxy Lacks Key Info
- PTAB Denies Novartis' Challenge To Cancer Drug Patents
- Pa. Judge Urged To Make J&J CEO Testify In Risperdal Trial
- Theranos Execs' Days Of Reckoning Draw Nearer
- Life Sciences Group Of The Year: White & Case
- Health Hires: Norton Rose, K&L Gates, Fox Rothschild
- The US Biosimilars Patent Litigation Outlook For 2019
- Settlement Counsel Key For Efficient Mass Tort Resolution
- Imerys Must Face Suit Alleging Talc Caused Woman's Cancer
- Medical Device Co.'s Del. Suit Says Competitor 'Sabotaged' It
- Spectrum Adds Shutdown To Deal Clock, Others Could Follow
- NYC Adds Sacklers, Drugstore Chains To Opioid Suit
- Lens.com Can't Ditch Or Move Alcon TM Suit, NY Judge Says
- Fla. Gov. Wants Legislature To Cut Medical Pot Smoking Ban
- Revance Prices $100M Preapproved Offering Amid Shutdown
- Hunger For New Drugs, Tech To Drive 2019 Pharma M&A
- Insulin Patients Impacted By Drug-Pricing Scheme, Court Told
- Chancery's Toss Of $3M Biotech Co. Breach Claim Stands
- PTAB Axes Fish Oil Patent In Post-Grant Review
- Stevens & Lee Nabs Ballard Partner For Tech Co-Chair Role
- Diversity's Next Step: Developing Minority Partners
- Takeaways From Fed. Circ. Hatch-Waxman IPR Case
- Alzheimer's Drug Co. Alzheon Again Nixes IPO Plans
- What Cannabis Patent Applicants Can Learn From Biopharma
- 2019 Annual Meeting And Reporting Considerations: Part 4
- Life Sciences Group Of The Year: Weil
- NJ Atty Seeks Revival Of Homeopathic Flu Remedy Fraud Suit
- Religious Bias Suit OK'd Over Pfizer's Iffy Arbitration Policy
- Curious Jury Gets Answers From Pathologist In J&J Talc Trial
- Mo. High Court Hits Pause On Looming J&J Talc Cancer Trial
- Outcome Health Adds Compliance Chief After Fraud Claims
- PetIQ Chews On Rivals' Fresh Suit Over Clinic Chain Buy
- Drugmakers Aim To Bump Delinquent Plaintiffs In Abilify MDL
- Hernia Mesh Maker Can't Revive IP Suit Coverage Bid
- J&J Renews Bid To End Antitrust Suit From Walgreens, Kroger
- Opioid Distributors Want 6th Circ. RICO Ruling Before Trial
- Insys Shareholders Want Stay Lifted In Fentanyl Chancery Suit
- Ariad Exec's Ex Gets 18 Months For Trading On Drug Info
- Opioid User Testimony To Be Key Factor In Mass. Insys Trial
- NY AG Wants Pharma Co.'s DOJ Settlement Docs
- Sichenzia Ross Steers Calif. Biopharma Firm On $20M IPO
- 2019 Annual Meeting And Reporting Considerations: Part 3
- 2018 Trends In HHS Corporate Integrity Agreements
- UK Patent Law: Hot Topics Of 2018 And What's Ahead
- Life Sciences Group Of The Year: Paul Weiss
- Arbitrators And Mediators Should Reflect Society's Diversity
- Purdue Brass Pinned Opioid Crisis On Addicts, Mass. AG Says
- Greatbatch Gets $22M In Redo Of Pacemaker Patent Trial
- Insurer Wants Out Of Covering Depomed In Opioid Litigation
- Gottlieb Says 400 FDA Staff Back On Inspections
- Chancery Trims Fee Award In Miramar Class Merger Challenge
- 2 Companies Join IPO Pipeline With Filings Totaling $47M
- Why AFAs Are Key To The Future Of Legal Practice
- Akorn Wants Derivative Suit Related To Failed Merger Axed
- Barr Walks Back Anti-False Claims Act Whistleblower Views
- Lewis Brisbois Lands Segal McCambridge Team In Philly
- What Conn. Opioid Ruling Means For Liability Insurers
- Life Sciences Group Of The Year: Latham & Watkins
- 2019 Annual Meeting And Reporting Considerations: Part 2
- Edwards Pays Boston Scientific $180M, Ending All IP Fights
- How A No-Deal Brexit Would Affect Life Sciences Cos.
- Skip Md.'s Bid To Revive Price-Gouging Law, Justices Urged
- Robitussin Buyer Seeks Cert. In Label Suit Against Pfizer
- Allergan's Attack On Drug Compounding Falls Flat
- Fed. Circ. Affirms Generics Win In Colitis Patent Suit
- Baker Botts Defeats Takeda's DQ Bid In Heartburn Drug Fight
- Biologist Found J&J Talc In Dying Woman's Tissue, Jury Hears
- J&J Faces Retrial After $151M Hip Implant Loss Reversed
- Mylan Fights To Put Consumer On Stand In Celgene Clash
- Teva Tries To Nix Investors' 'Defective' Price-Hike Suit
- House Oversight Launches Probe Over Top-Dollar Drugs
- 2 Biotech Firms, Chinese Lender File IPOs Totaling $192M
- Allergan, St. Regis Urge Justices To OK PTAB Tribal Immunity
- 2019 Annual Meeting And Reporting Considerations: Part 1
- Circuits Left To Develop FCA Discovery Case Law
- Ethicon Gets One Covidien Claim Tossed In Patent Dispute
- Med Tech Co.'s Jurisdiction Appeal Is Improper, Judge Says
- Ex-GC Returns To Lead Haynes And Boone Group In Dallas
- Pharmacy, PE Fund Back Judge's Trim Of $70M FCA Suit
- Exhibit List Ordered Trimmed After Insys Execs Blast Gov't
- The Trump Administration's Latest Drug Pricing Initiatives
- Judging A Book: Barron Reviews 'The Clamor Of Lawyers'
- Doc Who Shared Teen Patient Info With Drug Co. Avoids Jail
- Pharma. Co. Egalet's Ch. 11 Confirmed In Delaware
- Cannabis S Corps Should Reconsider Restructuring
- Life Sciences Group Of The Year: King & Spalding
- Handling Corporate Congressional Probes In The Trump Era
- The Firms That Dominated In 2018
- Law360 Names Practice Groups Of The Year
- Uncertain Deals Climate Persists After JPMorgan Conference
- DLA Piper Decries DQ From $45M Blue Cross Payment Fight
- DOJ's Slumping FCA Hauls Cloud Future Recovery Prospects
- Fed. Circ. OKs PTAB Save Of Patent Covering Pfizer's Toviaz
- 3 Takeaways From The PTAB's Cannabis Experience
- Chancery Decision In CytRx Attys' Fees Dispute Upheld
- Health Hires: Lewis Brisbois, Pierce Bainbridge, Bradley Arant
- FTC Must Appear In AndroGel Case Despite Shutdown
- The Case For Lawyer-Directed Litigation Funding In NY: Part 2
- 9th Circ. Tosses Suit Over 'Useless' Vitamin E Supplements
- Teva Inks $135M Settlement In Ill. Medicaid Fraud Case
- What All Attorneys Need To Know About The Shutdown
- J&J Knew Of Baby Powder's Link To Cancer In '71, Jury Told
- CytoDyn, Investors End Chancery Director Options Suit
- Patent Ineligibility Revamp Shouldn't Up Rejections: USPTO
- FDA Won't Add Black Box Warning To Blood Thinner Plavix
- '60 Minutes' Ethics Feud Ends In Opioid MDL
- House Dems Pass Spending Bills, But Impasse Far From Over
- Ex-Insys Sales Rep Loses Bid To Split From Upcoming Trial
- Biotech CEO Rips Prosecutors, Gets 27 Mos. For Fraud, Lies
- Pa. Judge Won't Toss Mesh Trial After Three-Week Delay
- 5th Circ. Affirms Ex-ArthroCare CEO's 20-Year Fraud Sentence
- The Case For Lawyer-Directed Litigation Funding In NY: Part 1
- Patenting Cannabis: A Look At The Numbers
- 2nd Circ. Upholds Ex-Hunton Atty's Insider Trading Conviction
- BakerHostetler Atty Faces Disqualification Bid In Opioid MDL
- Plaintiffs Attys Rip 'Dishonest' Ethics Complaint In Opioid MDL
- Ex-Pharma CEO's $100M Bank Fraud Trial Opens
- Biotech Co. Asks Del. Justices To Reverse $3M Breach Ruling
- Conn. Judge Tosses Cities' Suits Against Opioid Makers
- Full Fed. Circ. Rejects Vaccine Act Case, Overruling 2 Judges
- Biometrics Co. Dodges Claims It Bribed Foreign Execs
- Ex-Insys CEO Pleads Guilty, May Testify In Bribery Trial
- Insys Founder Need Not Comply With Subpoena, Judge Rules
- Patent Eligibility Lessons From PTAB's Use Of Berkheimer
- Accounting Treatment Pitfalls To Avoid In Life Sciences M&A
- RI Law May Force Atty To Face Malpractice Suit, Judges Say
- Health Care Fraud Enforcement In 2018, And 2019 Predictions
- 7 Questions To Add To Your Lateral Partner Questionnaire
- 'Botched' Merger Disclosures Put Ambry On Hook For $450K
- Ex-Novartis Exec Fired Over Study Objections, NJ Jury Told
- Full Fed. Circ. Urged To Review 'Unclear' Double-Patent Rules
- GSK, Laid-Off Workers Fight Over Denial Of Severance
- $3.3M Deal Over Unwanted Ad Faxes Receives Early OK
- Fla. Urges Appeals Court To Keep Medical Pot Smoking Ban
- FDA Focus: What Venable's Practice Chair Is Watching
- Farm Bill Brings IP Options For Breeders Of New Plants
- A Chat With Reed Smith Chief Marketing Officer Sadie Baron
- FDA Understood Proposed Fosamax Warnings, Justices Told
- J&J Baby Powder Caused Dying Woman's Cancer, Jury Told
- High Court Roundup: Justices Refuse To Hear 5 Patent Cases
- Tesaro Hit With Investor Suit Over $5B Merger Deal With GSK
- Justices Pass On Appeal Of Sanctions For Presuit Actions
- Cooley Guides Cancer-Focused Biotech's $115M IPO Filing
- Gov't Says Chicago Can't Object To $625M FCA Deal
- High Court Won't Take Up Depakote Birth Defect Suit
- Preemption In Pharmaceutical Cases: 2018 In Review
- High Court Denies Gilead FCA Case After DOJ Thumbs-Down
- Weil, Fenwick Steer Eli Lilly's $8B Loxo Oncology Buy
- 'Flexible Work' Makes Freelancing More Viable In BigLaw
- A Call To Permit Judicial Substitution In MDL Proceedings
- Judge Weinstein On Activism, Gobbledegook, Going Robeless
- Johns Hopkins, Others Lose Bid To Kill Syphilis Study Suit
- Up Next At High Court: Drugs, Copyrights And State Immunity
- USPTO Patent Eligibility Revamp Expected To Cut Rejections
- Drug Cos. Decry 'Flagrant' Ethical Lapses In Opioid Cases
- Synergy Pharma Negotiates, Locks In Ch. 11 Sale Procedures
- Medical Device Co. Gets Nod For Ch. 11 Financing
- Full Fed. Circ. Won't Revisit 'Blocking Patent' Ruling
- Brand Battles: Johnson & Johnson, Monster, Amazon
- Judge Won't Gag AGs In Generics Price-Fixing Case
- Attys Head To JPMorgan Conference In Shaky Deals Climate
- Drugmaker Perrigo Hit With Investor Suit Over Tax Audit
- Abiomed Escapes $2.1M Equity Suit Brought By Fired Exec
- Genomic Sequencing Cos. Face FTC Scrutiny On $1B Deal
- Taxation With Representation: Wachtell, Simpson, MoFo
- Eyes On FTC After Canada's Drug Sampling Probe Flops
- Health Hires: Locke Lord, Morgan Lewis, Amneal, Novant
- Esperion Inks Daiichi Licensing Deal For Cholesterol Drugs
- KKR Affiliate Loans Food Allergy-Focused Biopharma $170M
- Teva, GSK Want Lamictal Suit Paused To Appeal Class Cert.
- A Closer Look At New Pharmaceutical Hazardous Waste Regs
- Allergan, St. Regis Drop 2 Short-Lived Restasis IP Suits
- Mylan Gets 2030 Linzess Launch After Allergan Deal
- GYNs Get Third Try At Cynosure 'Vaginal Rejuvenation' Suit
- Bristol-Myers' $74B Celgene Buy Gives 2019 M&A Fast Start
- Hypertension Therapy Co. Closes $77M Funding Round
- FisherBroyles Snags Health Industry Counsel As Partner
- Ag Co. Can't Duck Decision Calling Products 'Pesticides'
- What To Expect From Technology-Assisted Review In 2019
- AGs Blast Generic Cos.' Bid To Gag Price-Fixing Comments
- Clinical Trials: 2018 Litigation And Guidance Roundup
- Monsanto Roundup Buyers Denied Cert. In Wis.
- Kirkland, Wachtell Steer Bristol-Myers' $74B Celgene Buy
- Health Care Drove Most Of $2.9B In 2018 FCA Recoveries
- Firestorm Engulfs Trump's 'Int'l Pricing Index' For Drugs
- Allergy Co.'s Antitrust Suit Recycles Failed Trial, BCBS Says
- Synergy Pharma Defends Ch. 11 Sale Plan After Objections
- Orrick Nabs 2nd Fenwick & West Tech IPO Pro
- NJ Medical Device Co. Seeks Financing In Del. Ch. 11
- Full Fed. Circ. Won't Touch MS Drug Patent Royalties Fight
- USPTO Takes Win-Or-Lose Atty Fee Rule To Supreme Court
- Justices Told Fed. Circ. Ruling Made Mayo A 'Dead Letter'
- 4 Post-Christmas IPO Filings Perk Up January Pipeline
- 2nd Bellwether Track Set In Opioid MDL
- 2019 Will Bring More Good News For Litigation Finance
- Top 5 Drug And Medical Device Developments Of 2018
- Manufacturers Face The Rise Of Global Class Actions
- Atlas Venture Lands $250M In Latest Fund
- Former Insys CEO Will Plead Guilty In Opioid Kickback Case
- The Hottest Patent Law Issues Of 2018
- Why More Law Firms Will Embrace Remote Work In 2019
- Health Care Cases To Watch In 2019
- Trials To Watch In 2019
- Native American Cases To Watch In 2019
- Patent Cases To Watch In 2019
- Life Sciences Cases To Watch In 2019
- California Cases To Watch In 2019
- Supreme Court Class Action Cases To Watch In 2019
- Pennsylvania Cases To Watch In 2019
- Massachusetts Trends And Cases To Watch In 2019
- New Jersey Cases To Watch In 2019
- Product Liability Cases To Watch In 2019
- Product Liability Regulation & Legislation To Watch In 2019